SG11201400210RA - Adjuvanted formulations of staphylococcus aureus antigens - Google Patents

Adjuvanted formulations of staphylococcus aureus antigens

Info

Publication number
SG11201400210RA
SG11201400210RA SG11201400210RA SG11201400210RA SG11201400210RA SG 11201400210R A SG11201400210R A SG 11201400210RA SG 11201400210R A SG11201400210R A SG 11201400210RA SG 11201400210R A SG11201400210R A SG 11201400210RA SG 11201400210R A SG11201400210R A SG 11201400210RA
Authority
SG
Singapore
Prior art keywords
staphylococcus aureus
aureus antigens
adjuvanted formulations
adjuvanted
formulations
Prior art date
Application number
SG11201400210RA
Other languages
English (en)
Inventor
Fabio Bagnoli
Barbara Baudner
Simone Bufali
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201400210RA publication Critical patent/SG11201400210RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11201400210RA 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens SG11201400210RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US201261607999P 2012-03-07 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (fr) 2011-09-01 2012-08-31 Formulations à adjuvant d'antigènes de staphilococcus aureus

Publications (1)

Publication Number Publication Date
SG11201400210RA true SG11201400210RA (en) 2014-03-28

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400210RA SG11201400210RA (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Country Status (14)

Country Link
US (1) US20140363461A1 (fr)
EP (1) EP2763695A1 (fr)
JP (1) JP2014525429A (fr)
KR (1) KR20140066212A (fr)
CN (1) CN104093418A (fr)
AU (1) AU2012300765A1 (fr)
BR (1) BR112014004782A2 (fr)
CA (1) CA2847204A1 (fr)
IL (1) IL231104A0 (fr)
IN (1) IN2014CN02152A (fr)
MX (1) MX2014002363A (fr)
RU (1) RU2014112343A (fr)
SG (1) SG11201400210RA (fr)
WO (1) WO2013030378A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115175A1 (fr) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Régulation de compositions de copolymères
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
JP2014507142A (ja) * 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス，インコーポレイテッド α溶血素オリゴペプチドを含む免疫原性組成物
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
IN2014CN02152A (fr) * 2011-09-01 2015-09-04 Novartis Ag
PL2822947T3 (pl) * 2012-03-07 2017-01-31 Glaxosmithkline Biologicals Sa Sole argininowe agonisty TLR7
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
CN110563818A (zh) * 2012-08-31 2019-12-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
CN104684570A (zh) * 2012-08-31 2015-06-03 诺华股份有限公司 用于免疫抵抗金黄色葡萄球菌的稳定化的蛋白质
WO2014033192A1 (fr) * 2012-08-31 2014-03-06 Novartis Ag Protéines stabilisées pour l'immunisation contre le staphylocoque doré
WO2015140108A1 (fr) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunisation contre les infections staphylococciques des os et des articulations
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
WO2015144691A1 (fr) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions destinées à l'immunisation contre staphylococcus aureus
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
EP3484518B1 (fr) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Conjugués d'adjuvant d'anticorps
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113993549A (zh) 2019-03-15 2022-01-28 博尔特生物治疗药物有限公司 靶向her2的免疫缀合物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (fr) 1983-01-25 1991-09-25 Ciba-Geigy Ag Dérivés peptidiques
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
CA2532370A1 (fr) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides pour l'induction d'une reponse immunitaire de protection contre le staphylococcus aureus
WO2005009378A2 (fr) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides utilises pour induire une reponse immunitaire vis-a-vis du staphylocoque dore
EP1725575B1 (fr) 2004-02-18 2012-11-28 Merck Sharp & Dohme Corp. Polypeptides d'induction d'une reponse immune protectrice contre staphylococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090192153A1 (en) 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939201A4 (fr) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Nouveau composé adénine
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
WO2007034916A1 (fr) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Nouveau composé adénine
MX2008010611A (es) 2006-02-17 2008-11-12 Pfizer Ltd Derivados de 3-desazapurina como moduladores de receptores similares a toll.
CN101466406B (zh) 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
EP2041135A4 (fr) 2006-07-05 2010-12-01 Astrazeneca Ab Dérivés de la 8-oxoadénine agissant comme modulateurs de tlr7
WO2008005555A1 (fr) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulateurs du récépteur tlr7 (toll-like receptor 7)
WO2008152447A2 (fr) 2006-10-30 2008-12-18 The University Of Western Ontario Anti-infectieux spécifiques de staphylococcus aureus
DE602008003764D1 (de) 2007-02-19 2011-01-13 Glaxosmithkline Llc Purinderivate als immunmodulatoren
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
BRPI0811125A2 (pt) 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolinas com propriedades imunomoduladoras
CA2707030A1 (fr) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
WO2009029831A1 (fr) 2007-08-31 2009-03-05 University Of Chicago Procédés et compositions associées pour immuniser contre des maladies et des états staphylococciques des poumons
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
WO2009111337A1 (fr) 2008-03-03 2009-09-11 Irm Llc Composés et compositions servant de modulateurs de l’activité des tlr
PT2276486E (pt) 2008-03-24 2013-12-04 4Sc Discovery Gmbh Novas imidazoquinolinas substituídas
EP2313111B1 (fr) 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Formulations d'agoniste des récepteurs de type toll et leur utilisation
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
SG175092A1 (en) * 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
TWI469789B (zh) * 2009-06-22 2015-01-21 Wyeth Llc 金黃色葡萄球菌抗原之免疫原性組合物
ES2625979T3 (es) 2009-07-16 2017-07-21 Glaxosmithkline Biologicals S.A. Tratamiento de infecciones
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
ES2458355T3 (es) * 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
IN2014CN02152A (fr) * 2011-09-01 2015-09-04 Novartis Ag
EP2822586A1 (fr) * 2012-03-07 2015-01-14 Novartis AG Formulations contenant un adjuvant d'antigènes de streptococcus pneumoniae
AU2013229432A1 (en) * 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
JP2015509963A (ja) * 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
CN110563818A (zh) * 2012-08-31 2019-12-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
WO2014033192A1 (fr) * 2012-08-31 2014-03-06 Novartis Ag Protéines stabilisées pour l'immunisation contre le staphylocoque doré
JP2015528456A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
CN104684570A (zh) * 2012-08-31 2015-06-03 诺华股份有限公司 用于免疫抵抗金黄色葡萄球菌的稳定化的蛋白质
JP6324961B2 (ja) * 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
EP2950819B1 (fr) * 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll
WO2015140108A1 (fr) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunisation contre les infections staphylococciques des os et des articulations
WO2015144691A1 (fr) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions destinées à l'immunisation contre staphylococcus aureus
EA037818B1 (ru) * 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены

Also Published As

Publication number Publication date
IL231104A0 (en) 2014-04-30
CN104093418A (zh) 2014-10-08
CA2847204A1 (fr) 2013-03-07
JP2014525429A (ja) 2014-09-29
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (pt) 2017-03-21
US20140363461A1 (en) 2014-12-11
EP2763695A1 (fr) 2014-08-13
WO2013030378A1 (fr) 2013-03-07
RU2014112343A (ru) 2015-10-10
MX2014002363A (es) 2014-04-14
IN2014CN02152A (fr) 2015-09-04
KR20140066212A (ko) 2014-05-30

Similar Documents

Publication Publication Date Title
IL231104A0 (en) Helper assemblies of antigens for Staphylococcus aureus
IL217084A0 (en) Immunogenic compositions of staphylococcus aureus antigens
HK1197370A1 (en) Stable immunogenic compositions of staphylococcus aureus antigens
HRP20171889T1 (hr) Formulacije kombinacije darunavira
EP2755680A4 (fr) Formulations vaccinales particulaires
IL229700A0 (en) Dronvir formulations
HK1207312A1 (en) Temperature stable vaccine formulations
ZA201409259B (en) Insecticidal formulations of microcapsules
EP2848257A4 (fr) Composition de vaccin pour prévenir une infection par staphylococcus aureus
ZA201305986B (en) Improved insecticide formulations
EP2892338A4 (fr) Mélange d'adjuvant pour des formulations pesticides
EP2638058A4 (fr) Enolase peptidiques vaccins conjugues contre staphylococcus aureus
EP2773655A4 (fr) Vaccin protecteur à base de protéine sa2074 de staphylococcus aureus
EP2773370A4 (fr) Vaccin prophylactique à base de la protéine sa2451 de staphylococcus aureus
GB201217868D0 (en) Staphyolococcus aureus antigens